Abstract
The Epstein-Barr virus (EBV) is a gammaherpesvirus that colonizes the B-cell system of its human host, allowing it to persist asymptomatically in the majority of the world's adult population. In most people primary infection goes unnoticed, whereas in a minority of individuals, primary infection results in infectious mononucleosis (IM), a benign condition that almost always resolves after several weeks or months. However, EBV is also causally linked with a number of malignancies, including B-cell lymphomas, such as classical Hodgkin lymphoma (cHL).
The detection of raised antibody levels to EBV antigens in Hodgkin lymphoma patients compared with other lymphoma patients provided the first clues that EBV might be involved in the pathogenesis of cHL .
(1) Furthermore, these raised levels were found to precede the development of cHL by In contrast to some other forms of EBVassociated B-cell lymphoma, the incidence of EBV-positive cHL is only modestly increased in patients infected with the human immunodeficiency virus (HIV) . The (16, 17) incidence of cHL in HIV-positive patients has not fallen during the era of highly active antiretroviral therapy (HAART); indeed, some studies suggest cHL risk may be increased in the first few months following immune reconstitution on HAART . These 
The non-tumor stroma of cHL is composed of T-cells, B-cells, macrophages, mast cells, eosinophils and fibroblasts, the composition of which appears to be important for patient outcomes . HRS cells can modify this (23, 24, 25, 26) reactive microenvironment by attracting certain cell types. For example, ReedSternberg cells secrete multiple chemokines such as CCL5 (RANTES), CCL17 (TARC), CCL20 and CCL22, which can recruit Th2
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